Overview

Study of ACE-1334 to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease

Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This Phase 1b/2 study is designed to assess the safety, efficacy, PK, and PD of ACE-1334 plus SOC in participants with diffuse Systemic Sclerosis (SSc) with or without ILD (Phase 1b) and SSc-ILD (Phase 2).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Acceleron Pharma Inc.